Sulfonylurea (SU) is considered first-line treatment of hepatocyte nuclear factor 1-alpha (HNF1A)-diabetes but rarely provides lasting glycemic control. In a randomized, double-blinded, cross-over study, we evaluated the insulinotropic effect of exogenous glucose-dependent insulinotropic peptide (GIP) and glucagon-like-peptide 1 (GLP-1), respectively, with and without SU in patients with HNF1A-diabetes. Ten patients with HNF1A-diabetes ([mean±SD] BMI 22.4±1.5 kg/m2; HbA1c 6.0±0.6% [42.3±6.6 mmol/mol]) and 10 matched healthy controls (BMI 22.2±2.4 kg/m2; HbA1c 5.1±0.3% [31.9±2.8 mmol/mol]) were subjected to six 2 h glucose clamps (time 0-60 minutes at fasting plasma glucose (FPG) and 60-120 minutes at 1.5 × FPG) preceded by administration of 1 mg of glimepiride or placebo (PLA) at time -90 min. Two-hour infusion of either GIP (1.5 pmol/kg/min), GLP-1 (0.5 pmol/kg/min) or saline (NaCl) was initiated at time 0 min. Insulin secretion was quantified as baseline-subtracted area under the curve (bsAUC) from 0 to 120 minutes (Figure). In patients with HNF1A-diabetes both SU+GIP and SU+GLP-1, respectively, showed significantly greater insulin secretion vs. PLA+GIP, PLA+GLP-1, SU+NaCl and PLA+NaCl, while this was only the case for SU+GLP-1 in controls.

In conclusion, GIP and GLP-1 potentiate SU-induced insulin secretion in patients with HNF1A-diabetes and in nondiabetic controls.


A.S. Christensen: None. S. Haedersdal: None. H. Storgaard: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc. K. Rose: None. N.L. Hansen: None. J.J. Holst: Advisory Panel; Self; Novo Nordisk A/S. T. Hansen: None. F.K. Knop: Advisory Panel; Self; AstraZeneca, MedImmune, Merck Sharp & Dohme Corp., Mundipharma, Novo Nordisk A/S, Sanofi. Consultant; Self; Amgen Inc., Carmot Therapeutics, Novo Nordisk A/S. Research Support; Self; AstraZeneca, Novo Nordisk A/S. Speaker's Bureau; Self; AstraZeneca, MedImmune, Merck Sharp & Dohme Corp., Mundipharma, Norgine, Novo Nordisk A/S. T. Vilsbøll: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at